Market News How it works Learn FAQ
| RCT 0.1382 81.60% | NU 11.97 -21.04% | TGL 0.2617 18.15% | EWZ 32.715 -23.19% | SRTM 0.3394 -21.12% | BBD 2.835 -30.34% | SHFS 0.0989 -25.30% | GCDT 0.1322 -24.93% | ITUB 7.368 -23.81% | NWGL 0.0817 -0.37% | CLRO 4.67 43.69% | XP 14.8623 -51.13% | AZTR 1.265 76.92% | RBNE 0.1664 -12.42% | PBR 21.535 -17.68% | SGRY 23.055 46.38% | SOXL 85.96 2.87% | TSLL 10.8899 11.58% | SPCX 147.535 0.03% | VALE 12.0045 -3.19% | SPRC 1.4499 33.02% | NVD 4.04 -3.58% | CRWV 54.96 1.34% | JBLU 2.2085 -15.87% | SOXS 51.01 -2.76% | INTC 87.29 0.38% | GPUS 0.1679 -0.59% | NVDA 215 1.92% | TSLA 394.1 5.88% | IREN 24.64 -1.06% | ABEV 2.7991 -15.18% | TQQQ 67.83 2.32% | RENT 2.9899 30.00% | NOK 8.46 3.93% | INTR 4.415 -38.60% | PBR-A 18.92 -19.59% | XTND 2.8083 58.66% | SQQQ 38.76 -2.32% | BITO 10.6402 -1.75% | LUCD 0.5437 32.29% | SPDN 8.495 -0.53% | VBIO 0.8098 -13.85% | SBS 4.765 -25.55% | XXII 0.0999 -49.47% | SID 0.9233 -21.75% | STNE 7.96 -30.66% | KORU 10.6 0.19% | WFF 0.0765 -4.38% | RWM 14.4501 -0.69% | TSLG 5.45 11.91%
MAMaze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE)

NASDAQ · Currency in USD
$31.42 ▲ +0.41 (+1.32%)
As of Oct 26, 11:26 AM ET. Market open.

Summary

Previous Close
$31.01
Open
$30.93
Day's Range
$30.84 – $31.63
52 Week Range
$21.95 – $53.65
Volume
65,388
Avg. Volume
678,439
Market Cap
$1.75B
Beta (5Y Monthly)
2.15
PE Ratio (TTM)
--
EPS (TTM)
-$2.26
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$75.00

Profile: Maze Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
141
CEO
Jason Coloma
Website
mazetx.com

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.76 · Revenue est. $333.33K
DateEst.Actual
Aug 12, 2026-$0.72-$0.76Miss
May 12, 2026-$0.43-$0.45Miss
Mar 25, 2026-$0.73-$0.65Beat
Nov 6, 2025-$0.74-$0.66Beat
Aug 12, 2025-$0.79-$0.77Beat
May 14, 2025-$0.76-$1.15Miss

Analyst view

Consensus price target
$75.00 ▲ +138.7%
Range $75.00 – $75.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on MAZE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.